Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting
16 mai 2019 07h00 HE
|
Stemline Therapeutics, Inc.
NEW YORK, May 16, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology...
Stemline Therapeutics Reports First Quarter 2019 Financial Results
10 mai 2019 06h30 HE
|
Stemline Therapeutics, Inc.
Net revenue for ELZONRIS was $5.05 million for the first quarterConference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics,...
Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019
08 mai 2019 07h00 HE
|
Stemline Therapeutics, Inc.
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology...
Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results
25 avr. 2019 07h00 HE
|
Stemline Therapeutics, Inc.
NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference
18 mars 2019 07h00 HE
|
Stemline Therapeutics, Inc.
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results
15 mars 2019 16h01 HE
|
Stemline Therapeutics, Inc.
NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline
11 mars 2019 07h00 HE
|
Stemline Therapeutics, Inc.
NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference
06 mars 2019 07h30 HE
|
Stemline Therapeutics, Inc.
NEW YORK, March 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)
30 janv. 2019 07h30 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Closes $92 Million Public Offering of Common Stock
18 janv. 2019 11h21 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...